|
ARHGEF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.29859464795368E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.16009465659317E-11 |
| Normal-vs-Stage2 |
3.87449999861289E-08 |
| Normal-vs-Stage3 |
9.36328792278118E-12 |
| Normal-vs-Stage4 |
2.03248529118127E-12 |
| Stage1-vs-Stage2 |
1.611970E-01 |
| Stage1-vs-Stage3 |
2.260600E-01 |
| Stage1-vs-Stage4 |
1.558190E-02 |
| Stage2-vs-Stage3 |
3.156200E-02 |
| Stage2-vs-Stage4 |
1.679740E-03 |
| Stage3-vs-Stage4 |
1.593370E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.44899647835928E-11 |
| Normal-vs-AfricanAmerican |
5.91119999948653E-07 |
| Normal-vs-Asian |
2.15819999649369E-08 |
| Caucasian-vs-AfricanAmerican |
2.803000E-01 |
| Caucasian-vs-Asian |
8.392200E-02 |
| AfricanAmerican-vs-Asian |
8.544600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.31720206858677E-11 |
| Normal-vs-Female |
2.78890244231889E-11 |
| Male-vs-Female |
8.295000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.46399583964308E-11 |
| Normal-vs-Age(41-60Yrs) |
1.03050012967287E-10 |
| Normal-vs-Age(61-80Yrs) |
7.8695938654505E-12 |
| Normal-vs-Age(81-100Yrs) |
1.976820E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.852000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.860600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.603600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.318000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.352600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.971000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.55829999962209E-07 |
| Classical-VS-Follicular |
2.594600E-01 |
| Classical-VS-Other |
8.848000E-01 |
| Classical-VS-Normal |
7.59200480260347E-11 |
| Tall-VS-Follicular |
1.71879999999458E-06 |
| Tall-VS-Other |
1.375370E-01 |
| Tall-VS-Normal |
1.62636570877339E-12 |
| Follicular-VS-Other |
6.414600E-01 |
| Follicular-VS-Normal |
9.83000003618173E-09 |
| Other-VS-Normal |
3.264400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.70530281404535E-11 |
| Normal-vs-N1 |
1.48010492750927E-11 |
| N0-vs-N1 |
1.091370E-01 |
|
|
